Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.

Vaughan CA, Singh S, Grossman SR, Windle B, Deb SP, Deb S.

Mol Oncol. 2017 Jun;11(6):696-711. doi: 10.1002/1878-0261.12068. Epub 2017 May 8.

2.

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.

Vaughan CA, Pearsall I, Singh S, Windle B, Deb SP, Grossman SR, Yeudall WA, Deb S.

Oncotarget. 2016 Mar 15;7(11):12426-46. doi: 10.18632/oncotarget.6998.

3.

Lung cancer stem cells, p53 mutations and MDM2.

Gadepalli VS, Deb SP, Deb S, Rao RR.

Subcell Biochem. 2014;85:359-70. doi: 10.1007/978-94-017-9211-0_19. Review.

PMID:
25201204
4.

MDM2 overexpression, activation of signaling networks, and cell proliferation.

Deb SP, Singh S, Deb S.

Subcell Biochem. 2014;85:215-34. doi: 10.1007/978-94-017-9211-0_12. Review.

PMID:
25201197
5.

p53: its mutations and their impact on transcription.

Vaughan C, Pearsall I, Yeudall A, Deb SP, Deb S.

Subcell Biochem. 2014;85:71-90. doi: 10.1007/978-94-017-9211-0_4. Review.

PMID:
25201189
7.

The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing.

Frum RA, Singh S, Vaughan C, Mukhopadhyay ND, Grossman SR, Windle B, Deb S, Deb SP.

Nucleic Acids Res. 2014 Jan;42(2):926-40. doi: 10.1093/nar/gkt944. Epub 2013 Oct 24.

8.

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S.

Genes Cancer. 2012 Jul;3(7-8):491-502. doi: 10.1177/1947601912462719.

9.

Generation of p53 knock-down cell lines.

Vaughan C, Deb SP, Deb S.

Methods Mol Biol. 2013;962:193-9. doi: 10.1007/978-1-62703-236-0_16.

PMID:
23150448
10.

Use of the DNA fiber spreading technique to detect the effects of mutant p53 on DNA replication.

Frum RA, Deb S, Deb SP.

Methods Mol Biol. 2013;962:147-55. doi: 10.1007/978-1-62703-236-0_12.

11.

Measurement of chemosensitivity and growth rate in p53 expressing cells.

Ramamoorthy M, Vaughan C, Deb S, Deb SP.

Methods Mol Biol. 2013;962:127-33. doi: 10.1007/978-1-62703-236-0_10.

PMID:
23150442
12.

Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A, Deb SP, Deb S.

Biochem Biophys Res Commun. 2012 Nov 9;428(1):6-10. doi: 10.1016/j.bbrc.2012.09.029. Epub 2012 Sep 16.

13.

Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.

Vaughan C, Mohanraj L, Singh S, Dumur CI, Ramamoorthy M, Garrett CT, Windle B, Yeudall WA, Deb S, Deb SP.

Genes Cancer. 2011 Oct;2(10):943-55. doi: 10.1177/1947601911436008.

14.

p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

Vaughan CA, Singh S, Windle B, Sankala HM, Graves PR, Andrew Yeudall W, Deb SP, Deb S.

Arch Biochem Biophys. 2012 Feb 1;518(1):79-88. doi: 10.1016/j.abb.2011.12.006. Epub 2011 Dec 16.

15.

Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.

Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, Windle B, Deb S.

Carcinogenesis. 2012 Feb;33(2):442-51. doi: 10.1093/carcin/bgr270. Epub 2011 Nov 22.

PMID:
22114072
16.

MDM2 controls the timely expression of cyclin A to regulate the cell cycle.

Frum R, Ramamoorthy M, Mohanraj L, Deb S, Deb SP.

Mol Cancer Res. 2009 Aug;7(8):1253-67. doi: 10.1158/1541-7786.MCR-08-0334. Epub 2009 Aug 11.

17.

Wild-type p53 and p73 negatively regulate expression of proliferation related genes.

Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D, Crane BM, Kiyono T, Windle B, Deb SP, Deb S.

Oncogene. 2008 Apr 17;27(18):2583-93. Epub 2007 Nov 5.

PMID:
17982488
18.

HDM2-binding partners: interaction with translation elongation factor EF1alpha.

Frum R, Busby SA, Ramamoorthy M, Deb S, Shabanowitz J, Hunt DF, Deb SP.

J Proteome Res. 2007 Apr;6(4):1410-7. Epub 2007 Mar 21.

19.

Tumor-derived p53 mutants induce NF-kappaB2 gene expression.

Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S.

Mol Cell Biol. 2005 Nov;25(22):10097-110.

20.
21.

Modulation of gene expression by tumor-derived p53 mutants.

Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S.

Cancer Res. 2004 Oct 15;64(20):7447-54.

22.

Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.

Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S.

Oncogene. 2004 May 27;23(25):4430-43.

PMID:
15077194
23.

Cell cycle regulatory functions of the human oncoprotein MDM2.

Deb SP.

Mol Cancer Res. 2003 Dec;1(14):1009-16. Review.

24.

Flow cytometric analysis of MDM2-mediated growth arrest.

Frum R, Deb SP.

Methods Mol Biol. 2003;234:257-67.

PMID:
12824538
25.

Transactivation and transrepression studies with p53.

Scian MJ, Frum R, Deb SP, Deb S.

Methods Mol Biol. 2003;234:93-110.

PMID:
12824527
26.

Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.

Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S.

Oncogene. 2002 Jan 10;21(2):176-89.

27.

Function and dysfunction of the human oncoprotein MDM2.

Deb SP.

Front Biosci. 2002 Jan 1;7:d235-43. Review.

PMID:
11779693
28.
29.

Differential modulation of cellular and viral promoters by p73 and p53.

Deb D, Lanyi A, Scian M, Keiger J, Brown DR, Le Roith D, Deb SP, Deb S.

Int J Oncol. 2001 Feb;18(2):401-9.

PMID:
11172610
31.

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S.

Mol Cell Biol. 1996 Nov;16(11):6009-19.

32.

The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.

Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M.

Biochem Biophys Res Commun. 1995 Dec 26;217(3):825-31.

PMID:
8554604
33.

Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter.

Shivakumar CV, Brown DR, Deb S, Deb SP.

Mol Cell Biol. 1995 Dec;15(12):6785-93.

34.

N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.

Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP.

Oncogene. 1995 Apr 6;10(7):1275-82.

PMID:
7731677
35.

Cell-type-specific induction of the UL9 gene of HSV-1 by cell signaling pathway.

Deb SP, Deb S, Brown DR.

Biochem Biophys Res Commun. 1994 Nov 30;205(1):44-51.

PMID:
7999061
36.

Wild-type human p53 activates the human epidermal growth factor receptor promoter.

Deb SP, Muñoz RM, Brown DR, Subler MA, Deb S.

Oncogene. 1994 May;9(5):1341-9.

PMID:
8152794
37.
38.

p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein.

Martin DW, Subler MA, Muñoz RM, Brown DR, Deb SP, Deb S.

Biochem Biophys Res Commun. 1993 Aug 31;195(1):428-34.

PMID:
8395834
39.

Analysis of the promoter sequences of the UL9 gene of herpes simplex virus type 1.

Deb SP, Deb S, Brown DR.

Biochem Biophys Res Commun. 1993 Jun 15;193(2):617-23.

PMID:
8390247
40.

Analysis of the herpes simplex virus type 1 OriS sequence: mapping of functional domains.

Martin DW, Deb SP, Klauer JS, Deb S.

J Virol. 1991 Aug;65(8):4359-69.

42.
43.
44.
45.

Only one of the origin binding forms of SV40 T antigen has helicase activity.

Deb SP, Partin K.

Biochem Biophys Res Commun. 1988 May 31;153(1):249-55.

PMID:
2837202
46.

Supplemental Content

Support Center